Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30251% above fair value
$4.65−0.13 (-2.72%)
Close on Nov 12, 2026Market cap $64.72MP/E –Yield –
Champions Oncology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Champions Oncology's ebitda for the twelve months ending Jul 31, 2026 was $290.00K, down 93.2% year over year. For fiscal 2026 it was $260.00K, down 95.8% from the year before. The highest annual figure on record is $6.15M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $260.00K | -95.8% |
| FY2025 | Apr 30, 2025 | $6.15M | – |
| FY2024 | Apr 30, 2024 | -$5.46M | – |
| FY2023 | Apr 30, 2023 | -$3.16M | -249.8% |
| FY2022 | Apr 30, 2022 | $2.11M | +63.2% |
| FY2021 | Apr 30, 2021 | $1.29M | – |
| FY2020 | Apr 30, 2020 | -$1.10M | -225.1% |
| FY2019 | Apr 30, 2019 | $876.00K | – |
| FY2018 | Apr 30, 2018 | -$994.00K | – |
| FY2017 | Apr 30, 2017 | -$6.64M | – |
| FY2016 | Apr 30, 2016 | -$10.16M | – |
| FY2015 | Apr 30, 2015 | -$13.02M | – |
| FY2014 | Apr 30, 2014 | -$6.05M | – |
| FY2013 | Apr 30, 2013 | -$6.02M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -$95.00K | – |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -$222.00K | – |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $65.00K | -98.7% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $542.00K | -52.1% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | -$169.00K | -109.5% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | -$1.61M | -801.7% |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $4.90M | – |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $1.13M | – |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $1.78M | – |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $229.00K | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -$2.10M | – |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -$1.47M | -359.4% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -$2.11M | -963.5% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -$2.12M | -2483.1% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -$1.88M | -253.6% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $567.00K | -6.9% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $244.00K | +71.8% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $89.00K | – |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $1.23M | -2.8% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $609.00K | +133.3% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $142.00K | -42.7% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -$480.00K | – |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $1.26M | +104.4% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $261.00K | -44.3% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $248.00K | – |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | -$1.70M | -3075.4% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $617.00K | – |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $469.00K | +10.1% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | -$432.00K | -172.1% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $57.00K | – |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | -$206.00K | -481.5% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $426.00K | +2030.0% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $599.00K | – |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | -$492.00K | – |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $54.00K | – |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $20.00K | – |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | -$577.00K | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | -$2.35M | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | -$1.36M | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | -$451.00K | – |
See a number that looks wrong?